MicroRNAs and Target Genes in Pituitary Adenomas

Feng, Yajuan; Mao, Zhigang; Wang, Xin; Du, Quan; Jian, Mengyao; Zhu, Danyan; Xiao, Zheng; Wang, Haijun; Zhu, Yiping

doi:10.1055/s-0043-123763

Cited by 31 publications

(31 citation statements)

References 76 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overexpression of miR-16 inhibits the proliferation of PA cells HP75 and promotes apoptosis by targeting HMGA2 expression [23]. However, the comprehensive and specific effects of miRNAs in PA invasion behavior are still rarely reported [24]. Thus, we recognized 55DEMs in IPAs by RNA sequencing analysis.…”

Section: Discussionmentioning

confidence: 99%

Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas

et al. 2019

View full text Add to dashboard Cite

Background: Dysregulation of microRNAs (miRNAs) plays a critical role during the occurrence and progress of pituitary adenomas (PAs). However, the roles of miRNAs in the invasiveness of PA are poorly understood. This study aims to more comprehensively and specific define the relationship between altered miRNA and PA invasion.Methods: The differential expression of miRNAs (DEMs) between invasive PAs (IPAs) and non-invasive PAs (NPAs) was explored by RNA sequencing and which functions were analyzed by gene ontology (GO) as well as Kyoto Encyclopedia of Genes and Genomes (KEGG). The miRNA-mRNA network was predicted with bioinformatics.Results: We identified 31 upregulated miRNAs and 24 downregulated miRNAs in IPAs compared with NPAs. GO analysis and KEGG pathway analysis showed the DEMs were mainly associated with cell proliferation and cell cycle pathway. In addition, on the count of predicted miRNA-mRNA network, two hub miRNAs were identified. Conclusions:Our results demonstrate the miRNA-mRNA network in detail, which suggest that miRNA may be a promising target in diagnosis and therapy for IPAs.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Their long list illustrates the heterogeneity of factors that can contribute to the formation of a tumor. While this complicates the choice of miRNAs to use for diagnostic purposes, miR-10b, miR-16, miR-26a, miR-503 and miR-514 have been found upregulated or downregulated in at least four different pituitary tumor subtypes and therefore could be superior markers for tumor screening [89]. On top of this, other studies found miR196a-2 and miR-212 to be deregulated in all pituitary tumor types.…”

Section: Micro-rnasmentioning

confidence: 99%

Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors

2020

View full text Add to dashboard Cite

Pituitary neuroendocrine tumors (PitNET) do not only belong to the most common intracranial neoplasms but seem to be generally more common than has been thought. Minimally invasive liquid biopsies have the potential to improve their early screening efficiency as well as monitor prognosis by facilitating the diagnostic procedures. This review aims to assess the potential of using liquid biopsies of different kinds of biomarker species that have only been obtained from solid pituitary tissues so far. Numerous molecules have been associated with the development of a PitNET, suggesting that it often develops from the cumulative effects of many smaller genetic or epigenetic changes. These minor changes eventually pile up to switch critical molecules into tumor-promoting states, which may be the key regulatory nodes representing the most potent marker substances for a diagnostic test. Drugs targeting these nodes may be superior for the therapeutic outcome and therefore the identification of such pituitary-specific cellular key nodes will help to accelerate their application in medicine. The ongoing genetic degeneration in pituitary adenomas suggests that repeated tumor profiling via liquid biopsies will be necessary for personalized and effective treatment solutions.

show abstract

“…Exosomes, in addition to transferring miRNAs, are used to transfer other information, such as DNA, mRNA, proteins, etc., from one cell to another, and tumor cells play a particularly important role in exosome production [ 7 ]. Progression from benign PAs to its aggressive forms is accompanied by cumulative changes at the molecular level, where miRNAs play a direct role [ 8 ]. Dysregulation of miRNAs in tumor cells is a hallmark of a tumor, and miRNAs can play a role as tumor suppressors or oncogenes depending on the cellular context and various functions of the target genes [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas

Beylerli

Beeraka

Gareev

et al. 2020

IJMS

View full text Add to dashboard Cite

Pituitary adenoma (PA) accounts for 10–15% of all intracranial neoplasms. Even though most pituitary adenomas are benign, it is known that almost 35% of them exhibit an aggressive clinical course, including rapid proliferative activity and invasion of neighboring tissues. MicroRNAs (miRNAs) are short single-stranded RNA molecules that can influence post-transcriptional regulation by controlling target genes. Based on research data on miRNAs over the past 20 years, more than 60% of genes encoding human proteins are regulated by miRNAs, which ultimately control basic cellular mechanisms, including cell proliferation, differentiation, and apoptosis. Dysregulation of miRNAs has been observed in a number of diseases, especially tumors like PA. A majority of miRNAs are expressed within the cells themselves. However, the circulating miRNAs can be detected in several biological fluids of the human body. The identification of circulating miRNAs as new molecular markers may increase the ability to detect a tumor, predict the course of a disease, plan to choose suitable treatment, and diagnose at the earliest signs of impending neoplastic transformation. Therapy of PAs with aggressive behavior is a complex task. When surgery and chemotherapy fail, radiotherapy becomes the treatment of choice against PAs. Therefore, the possibility of implementing circulating miRNAs as innovative diagnostic and therapeutic agents for PA is one of the main exciting ideas.

show abstract

MicroRNAs and Target Genes in Pituitary Adenomas

Cited by 31 publications

References 76 publications

Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas

Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas

Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors

MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas

Contact Info

Product

Resources

About